TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2889.
Locate Jan Aushadhi KendraClinical Overview
Pantoprazole (40mg) and Mosapride (15mg) is a fixed-dose combination combining a proton pump inhibitor with a selective 5-HT4 receptor agonist. Mosapride enhances acetylcholine release from postganglionic nerve endings of the enteric nervous system, promoting upper gastrointestinal motility and gastric emptying without dopamine D2 blockade or cardiac HERG channel inhibition. Indicated for GERD, reflux esophagitis, and chronic gastritis with delayed gastric emptying.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily before breakfast. Swallow whole with a glass of water.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Loose stools, abdominal pain, dry mouth, nausea, transient transaminase elevations, malaise. Rare/Severe: Fulminant hepatitis, jaundice, and severe thrombocytopenia.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in acute gastrointestinal hemorrhage or mechanical obstruction. Discontinue immediately if jaundice, dark urine, or liver function abnormalities develop. Safe cardiac profile (does not prolong QT interval unlike cisapride).
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or gastrointestinal treatment recommendations. Always consult a registered gastroenterologist or qualified medical practitioner before initiating, altering, or discontinuing any gastrointestinal medication or digestive therapy.
Pantoprazole Gastro Resistant Tablets 40 mg
Pantoprazole Gastro-Resistant Tablets (20mg, 40mg) is an oral substituted benzimidazole proton pump inhibitor on the WHO Model List of Essential Medicines. It covalently binds to the H+/K+-ATPase system at cysteine 813 and 822 on parietal cells, suppressing both basal and stimulated hydrochloric acid secretion for over 24 hours. Indicated for the treatment of duodenal ulcers, gastric ulcers, erosive esophagitis, gastroesophageal reflux disease (GERD), and pathological hypersecretory conditions including Zollinger-Ellison syndrome.
Pantoprazole Injection 40mg
Pantoprazole for Injection (40mg vial) is an intravenous proton pump inhibitor on the WHO Model List of Essential Medicines. It irreversibly binds to H+/K+-ATPase proton pumps on parietal cells, achieving profound, immediate acid suppression. Indicated for short-term IV treatment of acute peptic ulcer bleeding, prevention of rebleeding following endoscopic hemostasis, severe erosive esophagitis in patients unable to take oral medications, and Zollinger-Ellison syndrome / hypersecretory states.
Pantoprazole 40mg (Gastro-resistant) + Domperidone 30mg (Prolonged Release) Capsules
Pantoprazole (20mg/40mg enteric-coated) and Domperidone (10mg/30mg sustained/prolonged-release) is a fixed-dose combination antiulcer and prokinetic therapy. Pantoprazole irreversibly binds to the gastric H+/K+-ATPase proton pump on parietal cells, suppressing basal and stimulated hydrochloric acid secretion for >24 hours. Domperidone is a peripheral dopamine D2 receptor antagonist that accelerates gastric emptying and increases lower esophageal sphincter (LES) tone without crossing the blood-brain barrier. Indicated for gastroesophageal reflux disease (GERD) with reflux esophagitis, non-ulcer dyspepsia, diabetic gastroparesis, and acid peptic disorders associated with nausea, fullness, or early satiety.
Pantoprazole 40mg (Enteric Coated) + Levosulpiride 75mg (Sustained Release) Capsules
Pantoprazole (40mg enteric-coated) and Levosulpiride (75mg sustained-release) is a potent combination of a proton pump inhibitor and a prokinetic benzamide. Pantoprazole profoundly suppresses gastric acid synthesis by blocking H+/K+-ATPase pumps. Levosulpiride is the levorotatory enantiomer of sulpiride that selectively antagonizes dopamine D2 receptors in the enteric nervous system and acts as an agonist at 5-HT4 receptors, accelerating gastric and gallbladder emptying and improving antropyloric coordination. Indicated for severe GERD refractory to conventional prokinetics, diabetic gastroparesis, and functional dyspepsia with prominent postprandial distress syndrome.